February 27, 2009

To whom it may concern:

5-2-1 Daizawa, Setagaya Ward, Tokyo
Toho Pharmaceutical Co., Ltd.
(Tokyo Stock Exchange Securities Code: 8129)
Norio Hamada, President and CEO
contact:
Mamoru Ogino
Executive Corporate Officer,
Joint General Manager of Administration Division
(TEL: 03-4330-3735)

Notice of Acquisition Result of Company Stock
Through Off-Floor Trading (ToSTNeT-3) for Purchase of Company Stock

Toho Pharmaceutical Co., Ltd. hereby announces that the company acquired its own shares today as described below, in line with its yesterday’s announcement (made on February 26, 2009) about the acquisition of company stock.

1. **Reason of acquisition of company stock:** To make it possible to carry out a flexible capital policy.

2. **Type of stock acquired:** Common stock of this company

3. **Total number of shares acquired:** 786,300

4. **Total cost of stock acquired:** 938 yen / share (total 737,549,400 yen)

5. **Date of acquisition:** February 27, 2009 (Friday)

6. **Method of acquisition:** Purchase through the off-floor trading for company stock at the Tokyo Stock Exchange

(For Reference)
Details of Resolution Concerning Specific Acquisition of Company Stock (publicly announced on February 13, 2009)

1. Type of stock acquired: common stock of this company
2. Total number of shares acquired: 2,000,000 (limit)
3. Total cost of stock acquired: 2,500,000,000 yen (Limit)

Company Stock Held by the Company in Treasury as of February 27, 2009

1. Number of shares issued and outstanding (excluding common stock for treasury): 59,938,647
2. Number of shares held in treasury: 827,975